ALK’s EURneffy 1mg Secures the CHMP Positive Opinion to Treat Allergic Reactions in Children

Shots:The CHMP has recommended EURneffy 1mg (adrenaline nasal spray) to treat allergic reactions as well as idiopathic or exercise-induced anaphylaxis in children (≥4yrs. & 15-30kg)If granted, the approval would be valid in all 30 EEA states & will support an extension to the existing EURneffy 2 mg’s approval from Aug 2024 for emergency…

ByRidhi RastogiJanuary 30, 2026

INSIGHTS+

Disease of the Month – Urticaria

Shots: Characterized by an itchy skin rash, urticaria, commonly known as hives, is often triggered by allergic reactions to food, medications, or contact with irritants. PharmaShots’ Disease of the Month report aims to educate a broad audience about health conditions affecting communities across the globe. This monthly feature provides a comprehensive overview of each disease,…

ByDipanshu DixitJuly 31, 2025

NEWS

ARS Pharmaceuticals and ALK’s EURneffy Secures the MHRA’s Approval to Treat Allergic Reactions in Children

Shots:The UK’s MHRA has approved EURneffy 2mg (adrenaline nasal spray) to treat allergic reactions (anaphylaxis) in children (>30kg); commercially available in the UK by late Q3’25In Nov 2024, ARS Pharma granted ALK exclusive rights to commercialize neffy outside the US, incl. EU (as EURneffy), Canada, & select markets in exchange for $145M upfront, ~$320M…

ByRidhi RastogiJuly 21, 2025

ALK’s EURneffy 1mg Secures the CHMP Positive Opinion to Treat Allergic Reactions in Children

Disease of the Month – Urticaria

ARS Pharmaceuticals and ALK’s EURneffy Secures the MHRA’s Approval to Treat Allergic Reactions in Children

Contact US

FOLLOW US